On June 12, 2020 DCprime, the front-runner in the field of relapse vaccines, in collaboration with the University of Bergen, reported the presentation of a novel preclinical animal model tailored for cancer vaccine research at the virtual 25th European Hematology Association (EHA) (Free EHA Whitepaper) Congress (EHA) (Free EHA Whitepaper) (Press release, DCPrime, JUN 12, 2020, View Source [SID1234561871]). The humanized immunocompetent mouse model was applied to evaluate DCprime’s lead product DCP-001 as a standalone vaccine against leukemic cells, and will also enable future evaluation of DCP-001 in combination with chemotherapy or immune modulators. The full abstract and poster are available via the EHA (Free EHA Whitepaper) Meeting’s website.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This crucial animal model will be invaluable in advancing our pre-clinical knowledge of DCP-001 and its development could not have been accomplished without the expertise from our partners at the University of Bergen," said Jeroen Rovers, MD, PhD, Chief Medical Officer of DCprime. "We look forward to working closely with Bergen University on future research initiatives as well as within the public-private consortium AML-VACCiN that continues to drive the clinical development of DCP-001 despite the current challenges in clinical practice due to COVID-19."
"We are excited to support DCprime’s novel cancer relapse vaccine strategy as a potential future therapy to efficiently keep hematological cancers in check. Generating a mouse model that supports the xenograft of leukemic cell lines in conjunction with systemic engraftment of a human immune system, has been very instrumental to demonstrate the therapeutic potential of DCP-001 as a cell-based cancer vaccine," commented Professor Bjørn Tore Gjertsen, Department of Clinical Science at the University of Bergen
DCprime’s lead cancer relapse vaccine candidate DCP-001 is generated by transforming a proprietary leukemic cell, DCOne, into a whole cell-based cancer vaccine. Clinical data from a previously concluded phase 1 clinical study that was presented at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) (Free ASH Whitepaper) in December 2019 demonstrated DCP-001’s potential to prolong relapse-free survival and overall survival as an allogeneic, off-the-shelf cell-based vaccine in the post-remission setting.
DCP-001 is currently being evaluated in the international, multi-center, open-label proof-of-concept study ADVANCE-II with AML patients in complete remission, but with persistent measurable residual disease (MRD). The associated AML-VACCiN consortium receives support from the EU under the Horizon 2020 program. More information can be found at www.amlvaccin.eu.